Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
about
Future directions: lung aging, inflammation, and human immunodeficiency virusHIV infection, aging, and immune function: implications for cancer risk and preventionIncomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsEffects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaquesIn vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy.HIV-1 infection leads to increased transcription of human endogenous retrovirus HERV-K (HML-2) proviruses in vivo but not to increased virion production.Lack of evidence for mtDNA as a biomarker of innate immune activation in HIV infectionThe effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions.HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation LevelsThe impact of inflammation on cognitive function in older adults: implications for healthcare practice and researchIntegrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era.Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection.CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapyAntiviral factors and type I/III interferon expression associated with regulatory factors in the oral epithelial cells from HIV-1-serodiscordant couples.Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental deathHIV-infected adolescent, young adult and pregnant smokers: important targets for effective tobacco control programs.Study design issues in evaluating immune biomarkers.Effect of combination antiretroviral therapy on Chinese rhesus macaques of simian immunodeficiency virus infectionSerious Non-AIDS events: Immunopathogenesis and interventional strategies.The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies.Association Between XRCC1 and WRN as Genetic Markers of Stability and Susceptibility to Cancer in Patients with HIV/AIDS and Cancer: a Cross-Sectional StudyBrief report: Circulating markers of fibrosis are associated with immune reconstitution status in HIV-infected men.Study of Natural Cytotoxicity Receptors in Patients with HIV/AIDS and Cancer: A Cross-Sectional Study.
P2860
Q26996040-E11DD7C2-77F2-49BB-AB23-A963350BDE8FQ27004165-97455783-76A9-47F7-BC96-7E4D1782B77CQ27021524-6F088E00-6C7E-440D-B2EA-3E38BE893877Q28540858-E2DF158D-039A-4665-A79A-F25AD00A07A5Q33749579-3E213704-B0C7-4902-9F48-A48FD95C1234Q33909483-15F8A871-849F-452B-99F8-FC08C297AEC4Q34262010-537C9673-E0B9-47C9-BEFD-A1CBE913A21FQ34500351-46D699FC-925B-4BBA-ACFB-8EDC52EFA05DQ35030011-CE81D55C-17E3-436B-9022-22AB62FDB8A6Q35115728-6183851D-7191-492A-B44C-98204C382F4FQ35558823-1A6131AA-C3A2-44D4-B0F6-4237518F9401Q35588137-9EF66498-481B-41DC-BA50-C46A941E4C8FQ36079150-E5484B90-B693-46DE-913C-EF32FC2CD269Q36238363-CE4AC334-12EC-4A87-AB9C-0C3EBD6359AFQ36709815-755AC1E4-0E05-4A46-80AC-12D00EECCCFAQ36747108-7229442A-0613-4A94-8F1D-203167E1EE77Q36784163-EEB20B3E-BEE5-4A06-8171-C8AC573E9370Q36889962-403A8AAA-795B-419F-8159-186CA619C22BQ36956948-18ED1393-0F17-4210-9E7F-DEF2BBCF6AB7Q37030799-9BE921E8-E95F-46D1-AD9B-FFE42AC86EBCQ37184783-F4AEC319-8459-406A-A6CF-B32F2E2A9128Q37258308-85F8A3B0-0DE7-4AFD-AC0A-61E4645917CAQ37418140-AA68DB40-23DC-4743-ACBF-0D629407C94CQ37600137-587EDE71-8231-4C7D-9E36-41C167E5DCF2Q37992718-D2AF0DCB-20E5-4FD3-8D75-06196DC8A1BBQ40238760-7B3D2EEF-9796-4902-857E-F8677EDE9BF1Q48141762-C9E50801-8950-4028-B34F-16C86F5139DAQ51660836-80D2E3E5-EE3D-4632-86A8-135E680E5450
P2860
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
@ast
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
@en
type
label
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
@ast
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
@en
prefLabel
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
@ast
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
@en
P2093
P2860
P356
P1476
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
@en
P2093
Alan Embry
Brenda S Collins
Runa Musib
Sarah Read
Susan F Plaeger
P2860
P304
P356
10.1089/AID.2011.0213
P577
2011-09-27T00:00:00Z